[ad_1]
The researchers describe the different ways that COVID-19 can cause serious cardiovascular problems related to inflammation.
They also provide guidance on how to deal with these problems.
Possible problems with drugs currently being administered to combat this virus are also highlighted.
A recent study by the Beijing Union Medical College and the Chinese Academy of Medical Sciences concludes that cardiovascular anti-inflammatory therapies should be used to treat people with COVID-19 suffering from cardiovascular problems or diseases.
The results of the study were published in the English journal “Frontiers in Cardiovascular Medicine”.
Proven anti-inflammatory therapies should be used in the treatment of patients with COVID-19 who are at increased risk for cardiovascular problems or who have already developed cardiovascular disease.
How should people with severe COVID-19 be treated?
How should COVID-19 patients with cardiovascular problems be treated?
The research group was the first to widely debate the use of cardiovascular anti-inflammatory therapies for patients severely affected by COVID-19.
The study provides guidelines for the selection of specific cardiovascular anti-inflammatory therapies for people with COVID-19 that depend on the severity of the condition and the response of the affected person to therapy.
Additionally, the researchers note the known risks of treatments for the cardiovascular system that are currently being tested in people with COVID-19.
The risk of pneumonia and shortness of breath in people with COVID-19 is already known, but there is increasing evidence of serious cardiovascular problems related to the disease.
Inflammation plays an important role in the development and complications of cardiovascular disease.
The researchers noted that people with COVID-19 with stronger signs of an inflammatory reaction were more likely to experience serious cardiovascular events and also had an increased risk of death.
COVID-19 can cause cardiovascular problems related to inflammation.
The study identified several ways that COVID-19 could trigger cardiovascular problems.
The virus can directly infect heart tissue and cause inflammation, exacerbate existing cardiovascular problems, or trigger an exaggerated immune response in the body, the researchers report.
By investigating current promising treatments for COVID-19 and cardiovascular anti-inflammatory therapies, which have already been verified in clinical trials with positive results, the research group was able to highlight potentially effective treatments.
In such a case, it is recommended to carry out an anti-inflammatory treatment to support recovery.
Important note:
This article contains general information only and should not be used for self-diagnosis or treatment.
It cannot replace a visit to the doctor.
Some medications, such as lopinavir / ritonavir, interferon-a, ribavirin, azithromycin, and hydroxychloroquine, that are currently used to treat COVID-19 may actually increase the risk of cardiovascular failure, the research group explains.
Since these drugs, particularly antiviral agents, may be essential in the clinical treatment of people with COVID-19, cardiovascular protection strategies are urgently needed to improve the overall prognosis.
(how)
However, the researchers caution against the use of new preclinical drugs for the treatment of COVID-19 because of their effectiveness and unknown safety risks.
Additionally, caution should be exercised when using certain antiviral medications, some of which are currently being clinically tested for the treatment of COVID-19.
